Industrial Securities: Maintains "Overweight" rating on Alphamab Oncology-B (09966.HK), KN026 commercialization sets sail

Zhitong Finance APP has learned that Industrial Securities has issued a research report stating that it has adjusted the company's earnings forecasts and expects Alphamab Oncology-B (09966.HK) to achieve net profit attributable to shareholders of RMB 185 million / -260 million / -192 million in 2026-2028, maintaining an "Overweight" rating; the bank believes that the outbound licensing fully validates the global competitiveness of JSKN016 and the glyco site-specific conjugation platform, and the company's subsequent progress in outbound licensing of ADC molecules is worth anticipating.